Interim 2025-26 influenza vaccine effectiveness estimates reported for California residents

An interim observational report provided preliminary estimates of the 2025-26 seasonal influenza vaccine effectiveness among California residents. The analysis covered the period from October 2025 through January 2026. The specific vaccine formulation and a comparator group were not reported. The report stated that interim vaccine effectiveness estimates were available, but it did not provide the numerical effect size, absolute case numbers, p-values, or confidence intervals. The direction of the effect (e.g., positive or negative) was also not specified. Safety and tolerability data, including adverse events and discontinuations, were not reported in this interim analysis. The report did not list specific study limitations, but the nature of the data imposes important constraints. As an observational study, it can only show association, not prove causation. The findings are interim and not final results, and key metrics like effect size are missing. The practice relevance of this report was not specified. For clinicians, this interim report signals that early-season monitoring of the 2025-26 influenza vaccine is underway in California, but the absence of concrete numerical data prevents any clinical interpretation or action. Final, peer-reviewed estimates with complete statistical analyses are needed to assess the vaccine's performance.